

Claims

What is claimed is:

1. A method for detecting compounds that effect cell proliferation, comprising,
 - 5 a) adding to cells a composition comprising a compound suspected of effecting cell proliferation;
 - b) measuring cell proliferation; and
 - c) comparing cell proliferation in b) to cell proliferation in cells not treated with the compound.
- 10 2. The method of Claim 1, wherein cell proliferation is determined by measuring the amount of HSPG.
- 15 3. The method of Claim 3, wherein the HSPG is perlecan, syndecan or glypcan.
- 20 4. The method of Claim 2, wherein the HSPG is perlecan.
- 25 5. The method of Claim 1, wherein the compound is a chemical element, molecule, compound, mixture, emulsion, chemotherapeutic agent, pharmacological agent, hormone, antibody, growth factor, cellular factor, nucleic acid, protein, peptide, peptidomimetic, nucleotide, carbohydrate, and combinations, fragments, analogs or derivatives of such entities.
- 30 6. A composition, comprising, a compound capable of effecting cellular proliferation.
7. The composition of Claim 6, wherein the compound increases HSPG production.
8. The composition of Claim 6 wherein the compound decreases the production of HSPG.

9. The composition of Claim 6, wherein the compound is a chemical element, molecule, compound, mixture, emulsion, chemotherapeutic agent, pharmacological agent, hormone, antibody, growth factor, cellular factor, nucleic acid, protein, peptide, peptidomimetic, nucleotide, carbohydrate, and combinations, fragments, analogs or derivatives of such entities.

10

10. The composition of Claim 6, wherein the compound increases cell proliferation as determined by the method of Claim 1.

11. The composition of Claim 6, wherein the compound decreases cell proliferation as determined by the method of Claim 1.

15

12. The composition of Claim 6 wherein the composition comprises a nucleic acid vector.

13. The composition of Claim 6, further comprising a pharmaceutically acceptable carrier.

20

14. A method for treating vascular occlusive conditions, comprising, administering a composition comprising one or more compounds in an effective amount for inducing HSPG synthesis.

25

15. The method of Claim 14 wherein the HSPG is syndecan, glypcan or perlecan.

16. The method of Claim 14 wherein the vascular occlusive condition is atherosclerosis, thrombosis, transplant vasculopathy, cardiac allograft vasculopathy or restenosis.